India Pharma Outlook Team | Monday, 01 September 2025
Novavax declared that the U.S. Food and Drug Administration (FDA) has given its nod to the updated Nuvaxovid 2025-2026 Formula to stop COVID-19. The consent comprises those aged 65 and above, as well as the people between 12 and 64 suffering from health issues that may aggravate their condition due to COVID-19.
“Innovative medicines like Sanofi are going to Path B with today’s approval to provide a COVID-19 protein-based vaccine (non-mRNA) for the fall to those eligible,” said John C. Jacobs, President and CEO of Novavax.
The choice is supported by abundant safety and efficacy clinical data and corroborated by laboratory studies. The vaccine has been shown to provide a robust immune response to the JN.1 variant, the one causing the largest number of infections worldwide. Additionally, the shield has been found to be effective against several subvariants in circulation, such as NB.1.8.1, LP.8.1, XFG, XFC, LF.7, and XEC.
The more visible aspect of the cooperation between Novavax and Sanofi is the vaccine’s global dissemination. According to the deal, Sanofi will be in charge of worldwide commercialization while Novavax will get the royalties on the sales.
Also Read: Lilly's Oral GLP-1 Orforglipron Shows Success in Phase 3 Trial
Basically, this keeps the door open to other alternatives, specifically, those looking for extra protection, particularly at-risk groups. By taking the non-mRNA path, Novavax hopes to capture the attention of people who are willing to take a trusted and safe vaccine before the 2025–2026 respiratory care.
